Suzhou Fushilai Pharmaceutical Co., Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was CNY 548.95 million compared to CNY 511.66 million a year ago. Revenue was CNY 568.21 million compared to CNY 521.7 million a year ago.

Net income was CNY 177.3 million compared to CNY 120.2 million a year ago. Basic earnings per share from continuing operations was CNY 2.06 compared to CNY 1.75 a year ago. Diluted earnings per share from continuing operations was CNY 2.06 compared to CNY 1.75 a year ago.